- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101.
Stock Analysis

last close
$8.95
1-mo return
1.6%
3-mo return
-3.6%
avg daily vol.
403.33T
52-week high
17.62
52-week low
7.63
market cap.
$589M
forward pe
-
annual div.
-
roe
-230.8%
ltg forecast
2.7%
dividend yield
-
annual rev.
$--
inst own.
43.7%